A5037068166- Acute Myeloid Leukemia Research
- Histone Deacetylase Inhibitors Research
- Chronic Myeloid Leukemia Treatments
- Retinoids in leukemia and cellular processes
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- RNA Interference and Gene Delivery
- Transplantation: Methods and Outcomes
- Cancer therapeutics and mechanisms
- Synthetic Organic Chemistry Methods
- Acute Lymphoblastic Leukemia research
- Polyomavirus and related diseases
- Immune Cell Function and Interaction
- Pharmacological Effects of Natural Compounds
- Estrogen and related hormone effects
- Protein Degradation and Inhibitors
- Synthesis and biological activity
- Magnolia and Illicium research
- T-cell and B-cell Immunology
- Cell death mechanisms and regulation
- Synthesis and Characterization of Heterocyclic Compounds
- CAR-T cell therapy research
Shenzhen Second People's Hospital
2016-2024
Southern Medical University
2014-2022
Nanfang Hospital
2022
Zhujiang Hospital
2014-2016
Abstract Background The heterogeneity of relapsed or refractory (R/R) acute myeloid leukemia (AML) leads to no response venetoclax (VEN)–based therapy in more than half the patients. Genetic characteristics are considered important predictors for treatment adults with AML. However, association genetic outcomes receiving VEN‐based is incompletely understood R/R Objective To evaluate efficacy VEN combined hypomethylating agents (HMA) and identify potential Methods A total 150 AML patients...
<p>Supplementary Figure S4. Survival outcomes in VA and VAH patients depending on FLT3-ITD mutation.</p>
<p>Supplementary Figure S5. Incorporating HHT to overcome VEN resistance.</p>
<div>AbstractPurpose:<p>We investigated whether homoharringtonine (HHT) added to venetoclax plus azacitidine (VA) could improve outcomes and counteract the negative effects of genetic patterns in patients with relapsed/refractory acute myeloid leukemia (RR-AML).</p>Experimental Design:<p>A multicenter retrospective cohort study response VA HHT (VAH) versus regimens as salvage treatment RR-AML was performed. The endpoints were rates composite complete remission,...
<p>Supplementary Figure S3. Prognostic effect of VA and VAH on OS in genetic subgroups.</p>
<p>Supplementary Figure S2. Treatment response rates by co-mutations.</p>
<p>Supplementary Figure S1. Analysis of pairwise co-mutation and mutual exclusivity in the top 20 most frequently detected gene mutations.</p>
Acute promyelocytic leukemia (APL) is a special subtype of acute myeloid (AML), 95% patients have PML-RARA fusion gene as result reciprocal chromosomal translocation t(15;17)(q22; q21). The retinoic acid receptors (RARs) belong to nuclear hormone which modulate the transcription DNA elements. RARs three isoforms: receptor alpha (RARA), beta (RARB) and gamma (RARG). In this study, we describe experimental results case with HNRNPC::RARG transcript morphologic immunophenotypic features similar...
Abstract Purpose T(8;21)(q22;q22.1)/AML1-ETO positive acute myeloid leukemia (AE-AML) is sensitive to conventional chemotherapy with a favorable prognosis. However, recent small case reports suggest the limited effectiveness of venetoclax (VEN) and hypomethylating agents (HMA) in treating AE-AML. The aim this retrospective study was evaluate VEN plus AZA (VA) AE-AML explore whether adding homoharringtonine (HHT) VA (VAH) could improve response. Methods Patients who received HHT or regimens...
Low response, treatment-related complications and relapse due to the low sensitivity of myelodysplastic syndrome (MDS) leukemia stem cells (LSCs) or pre‑LSCs arsenic trioxide (ATO), represent main problems following treatment with ATO alone in patients MDS. To solve these problems, a chemosensitization agent can be applied increase susceptibility ATO. Curcumin (CUR), which possesses wide range anticancer activities, is commonly used for various types tumors, including hematopoietic...
Leukemia relapse and nonrecurrence mortality (NRM) due to leukemia stem cells (LSCs) represent major problems following hematopoietic cell transplantation (HSCT). To eliminate LSCs, the sensitivity of LSCs chemotherapeutic agents used in conditioning regimens should be enhanced. Curcumin (CUR) has received considerable attention as a result its anticancer activity solid tumors. In this study, we investigated cytotoxic effects underlying mechanisms stem-like KG1a exposed busulfan (BUS) CUR,...
Abstract Background Acute myeloid leukemia (AML) is a heterogeneous disease, and its heterogeneity associated with treatment response. Despite the demonstrated success of venetoclax (VEN)‐based therapy for AML, effect FLT3 mutations on efficacy poorly understood. We aimed to compare VEN‐based between FLT3‐mutated (FLT3 mut ) wild‐type wt patients identify predictors in patients. Methods A total 266 AML (127 newly diagnosed [ND] 139 refractory/relapsed [R/R]) receiving regimens were enrolled...
Acute myeloid leukemia (AML) is a common disorder in the elderly. Although remarkable progress has been made over recent decades, outcome remains poor. Thus, development of more effective method to overcome this problem necessary. In study, we aimed investigate synergistic cytotoxic effect low-dose arsenic trioxide (As2O3) combined with aclacinomycin A (ACM) on human AML cell lines KG-1a and HL-60, clarify underlying mechanism. Results showed that As2O3 ACM exerted by activation apoptosis...
Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and cause nonrelapse mortality after allo-HSCT. A conditioning regimen plays pivotal role in the development aGVHD. To provide platform for studying aGVHD evaluating impact different regimens, we established murine model that simulates clinical situation can be conditioned with Busulfan-Cyclophosphamide (Bu-Cy) Fludarabine-Busulfan (Flu-Bu). In our study, BALB/c...
This study was aimed to explore the effect of arsenic trioxide combined with curcumin on proliferation and apoptosis KG1a cells its potential mechanism. The cell survival rate mesured by MTT; colony formation capacity examined methylcellulose test; flow cytometry used analyse surface molecules, cycle; morphology observed Wright-Giemsa staining protein expression BCL-2, BAX, PARP detected Western blot. results showed that phenotype CD34(+)CD38(-), while HL-60 CD34(+)CD38(+). former possessed...
We investigated whether homoharringtonine (HHT) added to venetoclax plus azacitidine (VA) could improve outcomes and counteract the negative effects of genetic patterns in patients with relapsed/refractory acute myeloid leukemia (RR-AML).
This study was aimed to investigate the effect of Honokiol (HNK) on proliferation and apoptosis acute myeloid leukemia HL-60 cells its potential mechanism. Inhibitory HNK cell detected by MTT assay. Flow cytometry used detect change cycle AnnexinV/PI staining apoptosis. Western blot applied analyze protein (cyclins), cyclin-dependent kinase (CDK), P53, P21, P27, BCL-2, BCL-XL, Bax, caspase-3/9 proteins for MAPK signal pathway. The results showed that could inhibit in time- dose dependent...